Michelle M. Langhan

National Cancer Institute — United States

Medicine · Health Sciences

10h-index3.0kcitations43works19.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(41), CAR-T cell therapy research(30), Immunotherapy and Immune Responses(26), Lymphoma Diagnosis and Treatment(6), Immune Cell Function and Interaction(5)

Publications43 total

Publisher Correction: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Nature Medicine·2025· 4 cited
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Nature Medicine·2025· 35 citedOpen Access
Table S3 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Supplementary Data from A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
2023Open Access
Data from A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
2023Open Access
Table S1 and S2 from T-cell Responses to <i>TP53</i> “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
2023Open Access
Data from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Data from T-cell Responses to <i>TP53</i> “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
2023Open Access
Materials and Methods and Figures S1-S6 from T-cell Responses to <i>TP53</i> “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
2023Open Access
Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Supplementary Data from A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
2023Open Access
Figure S1 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Table S3 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Table S2 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
Table S1 and S2 from T-cell Responses to <i>TP53</i> “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
2023Open Access
Table S2 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Table S1 from Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
2023Open Access
Data from A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers
2023Open Access
Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Steven A. Rosenberg(43), Richard M. Sherry(29), James C. Yang(28), John R. Wunderlich(27), David N. Danforth(22), Thomas E. Shelton(19), Robert Somerville(19), Stephanie L. Goff(17), Udai S. Kammula(16), Mei Li M. Kwong(14), Zulmarie Franco(14), Samantha J. Seitter(13), Mackenzie L. Shindorf(13), Amy R. Copeland(13), Christine T. McGowan(13), Paul Robbins(13), Paul F. Robbins(12), Monica Epstein(12), Jared J. Gartner(11), Christian S. Hinrichs(11)